The overall goal of this HIVRAD Program is to develop a second generation HIV-1 vaccine based on recombinant adeno-associated virus (rAAV) vectors. The proposed research in this application builds on our experience with a first generation rAAV/HIV vaccine that is now being tested in Phase I human trials. Although the first generation vaccine is a promising candidate, we believe that substantial room for improvement remains. Based on our preliminary data, we have developed a series of hypothesis driven experiments to achieve this goal. We will enhance antigen-specific T cell responses to the vaccine by (i) significantly augmenting vaccine gene delivery and (ii) directly engaging and modifying host immune responses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI056354-02
Application #
6840242
Study Section
Special Emphasis Panel (ZAI1-CL-A (M4))
Program Officer
Pensiero, Michael N
Project Start
2004-09-30
Project End
2004-12-31
Budget Start
2004-09-30
Budget End
2004-12-31
Support Year
2
Fiscal Year
2004
Total Cost
$133,586
Indirect Cost
Name
Nationwide Children's Hospital
Department
Type
DUNS #
147212963
City
Columbus
State
OH
Country
United States
Zip Code
43205
Clark, K Reed; Walsh, Scott T R (2009) Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody. Protein Sci 18:2429-41
Chen, Chun-Liang; Jensen, Ryan L; Schnepp, Bruce C et al. (2005) Molecular characterization of adeno-associated viruses infecting children. J Virol 79:14781-92
Johnson, Philip R; Schnepp, Bruce C; Connell, Mary J et al. (2005) Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79:955-65